TCR2 THERAPEUTICS INC (TCRR)
US87808K1060 - Common Stock
Adaptimmune completes merger with fellow immunology company TCR2 (ADAP)
Adaptimmune (ADAP) said that it has completed its planned merger with fellow T-cell therapy developer TCR2 (TCRR). Read more here.
TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (TCR2 or the Company), a clinical-stage cell therapy company...
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel...
Global Pancreatic Cancer Competitive Landscape Report 2023: Comprehensive Insights about 250+ Companies and 300+ Drugs
/PRNewswire/ -- The "Pancreatic Cancer - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering. This "Pancreatic Cancer-...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FOCS, ROCC, TCRR
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates ROCC, KBAL, ADAP, TCRR
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RADI, ADAP, TCRR
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ROCC, RADI, ADAP, TCRR
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DSEY, ADAP, TCRR
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
TCR² and Adaptimmune announce strategic combination to create a preeminent cell therapy company focused on treating solid tumorsFollowing the expected Q2...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JNCE, ADAP, TCRR
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Moore Kuehn Encourages KBAL, DSEY, RADI, and TCRR Investors to Contact Law Firm
/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...
INVESTIGATION ALERT: Halper Sadeh LLC Investigates RADI, ADAP, TCRR, ROCC
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?
A new deal offers a lifeline for TCRR stock and a compatible investment for Adaptimmune. Both companies are targeting solid cancer tumors.
Shareholder Alert: Ademi LLP investigates whether TCR² Therapeutics Inc. has obtained a Fair Price in its transaction with Adaptimmune
/PRNewswire/ -- Ademi LLP is investigating TCR² (NASDAQ: TCRR) for possible breaches of fiduciary duty and other violations of law in its transaction with...
Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
Compelling clinical data with clear paths to products and multiple near‐term value-creating catalystsComplementary technology platforms designed to treat solid tumors...